Vexim extends SpineJack range of implants for treatment of vertebral fractures

Vexim, the Med-Tech specialist in the minimally invasive, anatomical treatment of vertebral compression fractures, today announced the extension of its SpineJack® range of implants. Two new sizes of implants (measuring 6.5 mm and 4.2 mm in diameter, respectively) will be added to the standard 5 mm size - enabling the SpineJack® to be used to treat almost all vertebral fractures of the spine.

"Although we were already addressing 80% of the vertebral fracture market with our standard, 5 mm implant, we decided to go a step further by completing the SpineJack® range with two new implants", emphasized Vexim's President and CEO Bruce de la Grange. "This range extension is in line with our strategy of not only covering almost the whole spine but also addressing a global market in which we have to adapt our products to local vertebral morphologies", he added.

Presentation of the two new titanium SpineJack® implants:

  • a 6.5 mm diameter model (CE marking in progress, with market launch planned in the coming months) for treating larger vertebrae (lumbar vertebras or other vertebrae in large patients).
  • a 4.2 mm diameter model (CE marking in progress, with market launch planned in the coming months) for treating smaller vertebrae (notably thoracic vertebrae or other vertebrae in smaller patients).

Source: Vexim

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.

or

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
TTUHSC researchers seek to understand TBX2's role in bone metastasis of prostate cancer